Researchers have discovered an experimental medication that significantly reduces a cholesterol-like particle that can ...

This is a major source of cardiovascular morbidity and mortality. We have never been able to treat lipoprotein(a) until now.” ...

A single dose of an experimental drug dramatically reduced levels of a deadly form of cholesterol, often thought to be ...

About a quarter of people risk heart attacks and strokes because they inherited a kind of cholesterol that statin drugs can’t ...

High levels of a chemical that is believed to be behind sudden and inexplicable heart attacks and strokes could soon have ...

A single dose of an siRNA molecule reduces elevated lipoprotein(a) — a major, but to date, largely untreatable risk factor ...

Heart disease experts are hailing the results of a clinical trial showed a strongly positive performance by a drug that ...

CHICAGO, IL—An investigational agent given by subcutaneous injection can drastically reduce levels of lipoprotein (a), with ...

Eli Lilly has linked lepodisiran to sustained reductions in a cardiovascular disease risk factor for nearly 1.5 years, ...

A new drug in clinical trials is showing promise in lowering a key genetic risk factor for heart attacks and ...

Lilly's drug is one of several being tested to treat high Lp(a), a risk factor for heart disease that affects an estimated ...

Eli Lilly’s lepodisiran, an investigational siRNA therapy, achieved significant and durable reductions in lipoprotein(a) ...